Jason Aryeh
CIK 1376960 · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$46.05M
Companies
11
Total Filings
171
Lifetime Open-Market Net
-$34.25M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LGND | Director | 120,580 | $255.54 | $30.81M | -$31.81M | 67 | 2026-06-12 |
| LFCR | Director | 69,967 | $5.64 | $394.6K | $0 | 3 | 2026-06-05 |
| OBIO | Director | 118,118 | $4.10 | $484.3K | $39.9K | 12 | 2026-05-20 |
| Anebulo Pharmaceuticals, Inc. (ANEB) Delisted | Director | — | $0.36 | — | $0 | 3 | 2025-04-07 |
| MERRIMACK PHARMACEUTICALS INC (MACK) Delisted | 10%+ Owner | 3,802 | $15.13 | $57.5K | $21.5K | 2 | 2019-07-18 |
| Aralez Pharmaceuticals Inc. (ARLZ) Delisted | Director | 15,000 | — | — | $1.17M | 4 | 2017-05-24 |
| NOVELION THERAPEUTICS INC. (NVLN) Delisted | Director | 369,924 | — | — | $3.2K | 2 | 2017-05-17 |
| IMMUNOMEDICS INC (IMMU) Delisted | Director | — | — | — | $0 | 1 | 2017-01-10 |
| QLTI | Director | 535,478 | $26.82 | $14.36M | $1.05M | 18 | 2016-06-21 |
| Myrexis, Inc. (MYRX) Delisted | Director | 9,900 | — | — | $1.15M | 19 | 2012-06-20 |
| Vaxart, Inc. (NABI) Delisted | Director | 131,783 | — | — | -$5.87M | 39 | 2011-05-27 |
Recent Filings · Page 13 of 18
171 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2011-03-16 | LGND | Buy (P) | +5,500 | $51.6K | EDGAR |
| 2011-03-16 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −3,400 | -$19.8K | EDGAR |
| 2011-03-15 | LGND | Buy (P) | +3,500 | $33.9K | EDGAR |
| 2011-03-15 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −24,700 | -$142.2K | EDGAR |
| 2011-03-14 | LGND | Buy (P) | +1,500 | $15.1K | EDGAR |
| 2011-02-23 | LGND | Buy (P) | +5,000 | $49.7K | EDGAR |
| 2010-12-29 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −15,093 | -$86.6K | EDGAR |
| 2010-12-29 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −1,907 | -$10.9K | EDGAR |
| 2010-12-17 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −1,907 | -$10.9K | EDGAR |
| 2010-12-10 | Vaxart, Inc. (NABI) Delisted | Sell (S) | −4,705 | -$25.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.